Advertisement

Randomized Multicenter 2 × 2-Factorial Design Study of Chemo/Endocrine Therapy in Operable, Node-Positive Breast Cancer (Protocol 2)

  • H. Scheurlen
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 115)

Abstract

In 1984, the West German Breast Cancer Study Group (see Appendix A) set up a controlled clinical trial on adjuvant therapy in “early” breast cancer to answer the following question: Is it possible to reduce six cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), to be given within 6 months starting perioperatively, to half the dose within half the time without decreasing the patient’s chance of survival? At that time, we started out from the following assumptions:
  1. 1.

    Polychemotherapy is superior to monotherapy (Fisher et al. 1981).

     
  2. 2.

    No other drug combination has so far been proved superior to the modified Bonadonna scheme (Bonadonna et al. 1981).

     
  3. 3.

    Twelve cycles of CMF can safely be reduced to six cycles (Bonadonna et al. 1981).

     
  4. 4.

    Early onset of adjuvant systemic chemotherapy is important: “Small is sensitive” (Nissen-Meyer 1982; Shackney et al. 1978).

     
  5. 5.

    Prolonged chemotherapy might be for the benefit of a small group of patients only, and therefore costs and benefits of cytotoxic chemotherapy in terms of side effects and gains in survival time should be taken into account.

     

Keywords

Breast Cancer Adjuvant Systemic Chemotherapy Cohort Study Control Prolonged Chemotherapy Nonrandomized Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Marchini S, Veronesi U (1981) Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes. The Milan Institute expericence. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer, vol 3. Grune and Stratton, New York, pp 435–444Google Scholar
  2. Consensus Conference (1985) Adjuvant chemotherapy for breast cancer. JAMA 254: 3461–3463CrossRefGoogle Scholar
  3. Eberbach WH (1988) Individual cases and the scientific method — a conflict? In: Scheurlen H, Kay R, Baum M (eds) Cancer clinical trials: a critical appraisal. Springer, Berlin Heidelberg New York Tokyo, pp 185–190 (Recent results in cancer research, vol 111 )Google Scholar
  4. Fisher B, Redmond C, Wolmark N, Wieland HS (1981) Disease-free survival at intervals during and following completion of adjuvant chemotherapy: The NSABP experience from three breast cancer protocols. Cancer 48: 1273–1280PubMedCrossRefGoogle Scholar
  5. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, Saffer E, Wickerham L, Lerner H, Glass A, Shibata H, Deckers P, Ketcham A, Oishi R, Russel I (1985) Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312: 665–673PubMedCrossRefGoogle Scholar
  6. Nissen-Meyer R (1982) The Scandinavian clinical trials. In: Baum M, Kay R, Scheurlen H (eds) Clinical trials in early breast cancer. Birkhauser, Basel pp 571–579Google Scholar
  7. Olschewski M, Scheurlen H (1985) Comprehensive cohort study: An alternative to randomized consent design in a breast preservation trial. Methods Inf Med 24: 131–134PubMedGoogle Scholar
  8. Scheurlen H, Schumacher M (1982) Planning breast cancer trials in the Federal Republic of Germany. Statistical Software Newsletter 2: 47–53Google Scholar
  9. Scheurlen H, Olschewski M, Leibbrand D (1984) Zur Methodologie kontrollierter klinischer Studien über die Primärbehandlung des operablen Mammakarzinoms. Strahlentherapie 160: 459–468PubMedGoogle Scholar
  10. Schumacher M, Davis K (1988) Combining randomized and nonrandomized patients in the statistical analysis of a clinical trial. In: Scheurlen H, Kay R, Baum M (eds) Cancer clinical trials: a critical appraisal. Springer, Berlin Heidelberg New York Tokyo, pp 130–137 (Recent results in cancer research, vol 111 )Google Scholar
  11. Shackney SE, McCormack GW, Cuchural GJ (1978) Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med 89: 107–121PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • H. Scheurlen
    • 1
  1. 1.Institut für Medizinische Biometrie und InformatikUniversität HeidelbergHeidelbergGermany

Personalised recommendations